Ständer S, et al. - In patients with atopic dermatitis treated with crisaborole, a non-steroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis (AD), researchers explored the connection between pruritus and quality of life (QoL). For this investigation, study participants aged ≥2 years were randomly assigned 2 : 1 to receive crisaborole:vehicle twice daily for 28 days. At baseline and on day 29, QoL was evaluated using the Dermatology Life Quality Index (DLQI; patients aged ≥16 years), the Children's Dermatology Life Quality Index (CDLQI; patients aged 2 to 15 years) and the Dermatitis Family Impact (DFI; caregivers of patients aged 2 to 17 years). To estimate links between pruritus (Severity of Pruritus Scale [SPS]) and QoL (DLQI, CDLQI and DFI in separate analyses), a repeated-measures longitudinal model was used. According to findings, the relationships between SPS and DLQI, CDLQI and DFI support the significant connection in AD between pruritus and patient/caregiver QoL.